A deeper understanding of EMT signalling may allow for the identification of additional novel therapeutic targets and strategies, in addition to reduction of TWIST1 itself, for the most aggressive types and subtypes of ovarian and other cancers. This evidence concerns the gene TWIST1 and cancer.